Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

Monday, February 23, 2026 at 11:36 AM

#Acquisition #Biotechnology #Cancer Drugs

Gilead Sciences Inc.

has agreed to acquire Arcellx Inc., a US-based cancer-focused biotechnology company, in a deal potentially worth up to $7.8 billion. Gilead, which already holds a 11.5% stake in Arcellx, will pay $115 per share in cash, with an additional $5 per share contingent on future sales.

This acquisition aims to bolster Gilead's drug pipeline. The offer price represents a significant premium, nearly doubling Arcellx's closing price from the previous trading day.

Arcellx shares saw a substantial increase in premarket trading following the announcement, while Gilead's stock experienced a slight dip.

Read More On

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billionwsj.com

Gilead to Buy Biotech Arcellx in Deal Worth Up to $7.8 Billion - Bloomberg.combloomberg.com

Gilead to buy Arcellx in nearly $8B deal - statnews.comstatnews.com

Gilead Sciences to Buy Arcellx in Deal Valuing Biotech at $7.8 Billion -- Update - marketscreener.commarketscreener.com

Gilead Sciences to Buy Arcellx in Deal Valuing Biotech at $7.8 Billion - marketscreener.commarketscreener.com

Markets★★★Similarity: 62% · 7d ago

Johnson Matthey Lowers Price of Unit Being Sold to Honeywell to $1.8 Billion

Johnson Matthey cut the price of the catalysts technologies unit that it is selling to Honeywell International by more than a quarter and extended the deadline for the closure of the deal.

Markets★Similarity: 62% · 11d ago

Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal

Hims & Hers Health has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion in an effort to expand its geographic reach.

Markets★★★Similarity: 62% · 4d ago

Victory Capital Files Competing Bid to Acquire Janus Henderson

Victory Capital said it submitted a bid to acquire Janus Henderson that it says is higher than the $7.4 billion offered in December by Nelson Peltz’s Trian Fund Management and venture firm General Catalyst.

Tech★★Similarity: 62% · 6d ago

Meta and AMD Agree to AI Chips Deal Worth More Than $100 Billion

The deal could result in Meta owning as much as 10% of AMD’s stock as the chipmaker seeks to challenge Nvidia.

Data sourced from public RSS feeds and News APIs.

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

Read More On

Related Articles

Johnson Matthey Lowers Price of Unit Being Sold to Honeywell to $1.8 Billion

Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal

Victory Capital Files Competing Bid to Acquire Janus Henderson

Meta and AMD Agree to AI Chips Deal Worth More Than $100 Billion

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

Read More On

Related Articles

Johnson Matthey Lowers Price of Unit Being Sold to Honeywell to $1.8 Billion

Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal

Victory Capital Files Competing Bid to Acquire Janus Henderson

Meta and AMD Agree to AI Chips Deal Worth More Than $100 Billion